KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to 15.61%.

  • Boston Scientific's EBITDA Margin rose 8100.0% to 15.61% in Q4 2025 from the same period last year, while for Dec 2025 it was 18.0%, marking a year-over-year increase of 24500.0%. This contributed to the annual value of 18.0% for FY2025, which is 24600.0% up from last year.
  • Boston Scientific's EBITDA Margin amounted to 15.61% in Q4 2025, which was up 8100.0% from 20.69% recorded in Q3 2025.
  • Boston Scientific's 5-year EBITDA Margin high stood at 20.69% for Q3 2025, and its period low was 5.76% during Q4 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 15.1% (2022), whereas its average is 14.68%.
  • Per our database at Business Quant, Boston Scientific's EBITDA Margin skyrocketed by 209100bps in 2021 and then plummeted by -22300bps in 2024.
  • Boston Scientific's EBITDA Margin (Quarter) stood at 5.76% in 2021, then soared by 115bps to 12.4% in 2022, then grew by 26bps to 15.68% in 2023, then fell by -6bps to 14.8% in 2024, then increased by 5bps to 15.61% in 2025.
  • Its EBITDA Margin was 15.61% in Q4 2025, compared to 20.69% in Q3 2025 and 16.18% in Q2 2025.